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Abstract The protein encoded by the ACRl gene in Saccha-
romyces cerevisiae belongs to a family of 35 related membrane 
proteins that are encoded in the fungal genome. Some of them are 
known to transport various substrates and products across the 
inner membranes of mitochondria, but the functions of 28 
members of the family are unknown. The yeast ACRl gene was 
introduced into Escherichia coli on an expression plasmid. The 
protein was over-produced as inclusion bodies, which were 
purified and solubilised in the presence of sarkosyl. The 
solubilised protein was reconstituted into liposomes and shown 
to transport fumarate and succinate. Its physiological role in S. 
cerevisiae is probably to transport cytoplasmic succinate, derived 
from isocitrate by the action of isocitrate lyase in the cytosol, 
into the mitochondrial matrix in exchange for fumarate. This 
exchange activity and the subsequent conversion of fumarate to 
oxaloacetate in the cytosol would be essential for the growth of 
S. cerevisiae on ethanol or acetate as the sole carbon source. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The glyoxylate pathway is one of the main anaplerotic 
routes for replenishing the intermediates of the tricarboxylic 
acid cycle that have been withdrawn for biosynthetic pur-
poses. In the yeast Saccharomyces cerevisiae, this pathway is 
essential for aerobic growth on either ethanol or acetate as the 
sole carbon source. Ethanol is converted to acetate via ace-
taldehyde, and then the acetate is activated to acetyl-CoA, 
and fed into the glyoxylate and tricarboxylic acid cycles. 
Two inducible enzymes in the yeast glyoxylate pathway, iso-
citrate lyase and malate synthase, are in the cytosol [1,2], 
whereas in plants they are confined to the glyoxysome [3]. 
The other enzymes implicated in the pathway (malate dehy-
drogenase, citrate synthase and aconitase) are present in both 
the cytosol and the mitochondrion, where they participate in 
the tricarboxylic acid cycle. Thus, succinate, one of the prin-
cipal products of this pathway, is produced in the cytosol 
from isocitrate. How does it replenish the succinate pool 
available to the tricarboxylic acid cycle in the matrix of the 
mitochondrion? In order to investigate this and related ques-
tions, mutant strains of S. cerevisiae have been selected for 
their inability to grow on ethanol as the sole carbon source. 
One such mutation is in the ACRl gene [4]. It encodes a 
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member of a family of 35 membrane proteins [5], whose bio-
chemically characterised members are involved in the trans-
port of substrates and products across the inner membranes 
of mitochondria [6-8]. Identified members in S. cerevisiae in-
clude three isoforms of the ADP/ATP translocase [9-11], and 
the phosphate [12], dicarboxylate [5,13], citrate [14] and orni-
thine [15] carriers. 
In the present work, we have identified ACRl as a trans-
porter for succinate and fumarate. Therefore, it is probably 
responsible for carrying cytosolic succinate produced by the 
glyoxylate pathway into the mitochondrion in exchange for 
fumarate, which is transported from the mitochondrial matrix 
to the cytosol. 
2. Materials and methods 
2.1. Materials 
NEM Life Science Products (Milan, Italy) supplied the sodium salt 
of oc-[l-14C]ketoglutaric acid. Egg-yolk phospholipids (egg lecithin) 
were obtained from Fluka (Milan, Italy), and cardiolipin and sarkosyl 
(TV-lauroylsarcosine) from Sigma Chemical Company (Milan, Italy). 
The molecular weight marker kit 12.3-78.0 kDa was purchased from 
BDH (Poole, UK). 
2.2. Amplification of the ACRl gene from yeast genomic DNA 
Oligonucleotide primers were synthesised with the sequences 5'-
TAGGGATCCCATATGTCTCAAAAAAAGAAGGCTTCC-3' and 
5'- CGAAAGCTTTTACTTTAATGGCTTTGGCTTTGG-3'. They 
correspond to the extremities of the coding sequence for ACRl (nu-
cleotides 609464-610429 on the positive strand of chromosome X; 
GenBank accession numbers Z25485, Z49595), followed by the stop 
codon TAA, and with Ndel and Hindlll sites at the 5' and 3' ends, 
respectively. The sequence of interest was amplified from S. cerevisiae 
genomic DNA, cloned into the expression vector pMW172, trans-
formed into Escherichia coli DH5a cells, and transformants were se-
lected and screened by direct colony PCR, as described before [5,15]. 
The sequence of the insert coding for ACRl was verified by the 
modified dideoxy chain termination method [16]. 
2.3. Bacterial expression and functional reconstitution of ACRl 
The ACRl protein was over-expressed at 37°C in E. coli C0214 
(DE3) [15]. Control cultures containing the empty pMW172 vector 
were processed in parallel. Inclusion bodies were obtained and puri-
fied as described previously [5,15,17]. ACRl was solubilised from the 
purified inclusion bodies in the presence of sarkosyl (2%, w/v), diluted 
1.5-fold with a buffer containing 2 mM PIPES, pH 7.0, 0.6% (w/v) 
Triton X-114 and 0.2 mM EDTA, and then reconstituted into lip-
osomes in the presence of appropriate substrates, as described before 
[5,15,17], except that cardiolipin (1 mg/ml) was included in the recon-
stitution mixture. 
2.4. Protein chemical characterisation of ACRl 
Samples taken from cultures at various points of growth and puri-
fied inclusion bodies were examined by SDS-PAGE in 17.5% gels. 
Either the proteins were stained with Coomassie blue dye or they 
were transferred to poly(vinylidene difluoride) membranes, stained 
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with Coomassie blue dye, and their N-terminal sequences determined 
with a pulsed liquid protein sequencer (Applied Biosystems Model 
All A). The yield of purified ACR1 per litre of bacterial culture was 
estimated from a Coomassie blue-stained SDS-PAGE gel with an 
LKB 2202 Ultroscan laser densitometer, with carbonic anhydrase as 
protein standard. 
2.5. Activity assays 
External substrate was removed from proteoliposomes on a Sepha-
dex G-75 column. The transport activity at 25°C was determined by 
measuring the flux of 14C-substrate from either outside to inside (for-
ward exchange) or inside to outside (backward exchange) [18]. In 
backward exchanges, the internal substrate pool of the proteolipo-
somes was made radioactive by carrier-mediated exchange equilibra-
tion with 5 uM [14C]oxoglutarate added at high specific radioactivity. 
After 30 min, residual external radioactivity was removed by passing 
the proteoliposomes again through a column of Sephadex G-75. In 
forward exchange reactions, transport was started by adding radio-
active substrate to the proteoliposomes, and in backward exchanges, 
by adding non-radioactive substrate. In both cases, exchange was 
stopped by addition of 30 mM pyridoxal 5-phosphate and 10 mM 
bathophenanthroline. In control samples, the inhibitors were added at 
the beginning together with the external substrate. Finally, the exter-
nal substrate was removed [18] and the radioactivity in the liposomes 
was measured [18]. In forward exchange kinetic experiments, the 
transport rate was calculated in umol/min per mg protein from the 
radioactivity taken up by the proteoliposomes within 1 min. In back-
ward exchange experiments, the decrease in radioactivity inside the 
liposomes before equilibrium was fitted to a single exponential decay 
equation plus offset. The initial rate was derived from this curve. The 
backward exchange rates were expressed as apparent velocities (i>'), 
which are proportional to the actual transport rates (v), the product of 
v' and the volume of liposomes containing the active ACR1. The 
active internal volume can be determined only with low accuracy, 
but it is constant for each experiment. Therefore, the relative back-
ward exchange velocities v' are suitable for the kinetic investigations 
described here. A similar procedure has been used before in kinetic 
analysis of the aspartate/glutamate, oxoglutarate, dicarboxylate and 
carnitine carriers [19-22]. 
Fig. 1. Expression of yeast ACR1 in E. coli. Proteins were separated 
by SDS-PAGE and stained with Coomassie blue dye. The position 
of ACR-1 is indicated by an arrow on the right. Lanes M, markers 
(hen egg ovotransferrin, bovine serum albumin, ovalbumin, carbonic 
anhydrase, myoglobin and cytochrome c); lanes \-A, E. coli 
C0214(DE3) containing the expression vector, without (lanes 1 and 
3), and with the coding sequence of ACR1 (lanes 2 and 4). Samples 
were taken at the time of induction (lanes 1 and 2) and 5 h later 
(lanes 3 and 4). The same number of bacteria was analysed in each 
sample. Lane 5, purified ACR1 (12 |xg) originating from bacteria 
shown in lane 4. 
3. Results and discussion 
Table 1 
The dependence on internal substrate of the transport properties of 
proteoliposomes containing bacterially expressed yeast ACR1 
Internal substrate Oxoglutarate transport % of 
(nmol/min/mg protein) exchange rate 
1.1 
97.6 
100 
97.4 
62.2 
61.5 
26.9 
5.5 
5.4 
13.1 
23.1 
26.9 
10.4 
2.7 
4.0 
4.2 
3.6 
6.3 
2.4 
3.9 
1.3 
1.8 
Proteoliposomes containing ACR1 were pre-loaded internally with 
various substrates (concentration 20 mM). Transport was started by 
the external addition of 1.5 mM [14C]oxoglutarate, and stopped after 
1 min. Similar results were obtained in three independent experiments. 
None (Cl- present) 
Succinate 
Fumarate 
Methylfumarate 
Oxoglutarate 
Oxaloacetate 
L-Malate 
Maléate 
Malonate 
Citrate 
c/s-Aconitate 
Threo-Ds -isocitrate 
Phosphoenolpyruvate 
Glutamate 
Aspartate 
Phosphate 
Sulphate 
Pyruvate 
Carnitine 
Ornithine 
ADP 
ATP 
16 
1425 
1460 
1422 
908 
898 
393 
80 
79 
191 
337 
393 
152 
39 
58 
61 
53 
92 
35 
57 
19 
26 
3.1. Bacterial expression of ACR1 
ACR1 over-expressed in E. coli C0214(DE3) (see Fig. 1, 
lane 4) has an apparent molecular mass of about 35.5 kDa 
(its calculated molecular mass is 35,341, including the initiator 
methionine). The protein, which appears as a single band in 
SDS-PAGE after purification from the inclusion bodies (Fig. 
1, lane 5), was not detected in bacteria harvested immediately 
before induction of expression (lane 2), nor in cells lacking the 
ACR1 coding sequence in the expression vector, harvested 
after induction (lane 3). The N-terminal sequence of the 
over-expressed protein was SQKKKASHPA, identical to the 
predicted sequence of residues 2-11 of ACR1. About 75 mg of 
purified protein (see Fig. 1, lane 5) was obtained per litre of 
bacterial culture. 
3.2. Substrate specificity and inhibitor sensitivity 
The reconstituted ACR1 catalysed a [14C]oxoglutarate/oxo-
glutarate exchange, but not the homo-exchanges of phos-
phate, pyruvate, malonate, glutamate, aspartate, glutamine, 
carnitine, ornithine, ADP and ATP (external concentrations 
1 mM, internal concentrations 20 mM, transport for 10 min). 
No oxoglutarate/oxoglutarate exchange activity was associ-
ated with sarkosyl-solubilised material from bacterial cells ei-
ther lacking the expression vector for ACR1, or harvested 
immediately before induction of expression of ACR1. 
The substrate specificity of ACR1 was investigated in great-
er detail by measuring the uptake of [14C]oxoglutarate into 
proteoliposomes that had been pre-loaded with a variety of 
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Fig. 2. Dependence of the rate of [14C]oxoglutarate/fumarate ex-
change in proteoliposomes containing reconstituted ACR1 on the 
external oxoglutarate concentration, and competitive inhibition by 
succinate and fumarate. [14C]Oxoglutarate was added at the concen-
trations indicated to proteoliposomes containing 20 mM fumarate. 
Except in the controls (o), 0.8 mM succinate ( • ) or 0.6 mM fuma-
rate (n) was added simultaneously with the [14C]oxoglutarate. 
by changing the concentration of externally added 
[14C]oxoglutarate at a constant internal concentration of 20 
mM fumarate. The Km and Fniax values for oxoglutarate ex-
change at 25°C from a typical experiment (see Fig. 2) were 2.1 
mM and 3.0 (jmol/min per mg protein, respectively. The aver-
age values of Km and Fmax from 24 experiments were 
2.0 ± 0.11 mM and 2.8 ± 0.7 (xmol/min per mg protein, respec-
tively. The rather high standard error of the Vmax values 
probably arises from variations in the amount of active carrier 
molecules present in the different preparations of the purified 
carrier. Succinate and fumarate inhibited the [14C]oxo-
glutarate/fumarate exchange in a competitive manner (see 
Fig. 2). The inhibition constants, K¡, 0.77 mM for succinate 
and 0.26 mM for fumarate, show that the carrier has a higher 
affinity for these two dicarboxylates than for oxoglutarate. 
Since ACR1 catalyses a counter-exchange of internal and 
external molecules across the membrane, the half-saturation 
substrates (see Table 1). In the absence of internal substrate, 
uptake of labelled oxoglutarate was not observed. The highest 
activities were detected in the presence of internal succinate, 
fumarate and methylfumarate. There was also significant ac-
tivity with internal oxoglutarate and oxaloacetate. To a much 
lesser extent, L-malate, c¿y-aconitate and isocitrate were ex-
changed for external [14C]oxoglutarate, and to a very low 
extent so were citrate and phosphoenolpyruvate. Virtually 
no exchange was observed with internal maléate, malonate, 
glutamate, aspartate, phosphate, sulphate, pyruvate, carnitine, 
ornithine, ADP, ATP and (not shown) glutamine, alanine and 
leucine. These results indicate clearly that radioactive oxoglu-
tarate is transported into proteoliposomes containing ACR1, 
only in exchange for an internal counter-substrate, the best of 
which are succinate and fumarate. 
The [14C]oxoglutarate/fumarate exchange reaction catalysed 
by reconstituted ACR1 was inhibited by sulphydryl reagents 
(mersalyl, /)-chloromercuribenzene sulphonate and mercuric 
chloride), by pyridoxal 5-phosphate and by bathophenanthro-
line (see Table 2). The impermeable dicarboxylate and tricar-
boxylate analogues phenylsuccinate, benzylmalonate and 
1,2,3-benzenetricarboxylate inhibited the reconstituted trans-
port activity strongly. In contrast, inhibitors of the pyruvate, 
ADP/ATP and phosphate carriers, oc-cyanocinnamate, car-
boxyatractyloside and N-ethylmaleimide, respectively [23-
25], had little or no effect on the activity of ACR1. 
The ability of non-radioactive potential substrates to inhibit 
the oxoglutarate/fumarate exchange was examined also (Table 
2). In general, the exchange was prevented by external addi-
tion of each of the substrates that are transported by ACR1 
(Tables 1 and 2), and it was unaffected by substrates of other 
mitochondrial carriers such as phosphate, glutamate and or-
nithine. However, poor substrates, such as isocitrate and 
phosphoenolpyruvate, as well as the dicarboxylates maléate 
and malonate, which are not transported at all by the 
ACR1 protein, inhibited the exchange activity significantly, 
suggesting that they bind to the substrate binding site of 
ACR1. 
3.3. Kinetic characteristics of reconstituted ACR1 
In order to obtain kinetic information about the 
[14C]oxoglutarate/fumarate exchange, the dependence of the 
exchange rate on substrate concentration was investigated 
Table 2 
Effect of inhibitors and externally added substrates on the 
[14C]oxoglutarate/fumarate exchange by proteoliposomes containing 
ACR1 
Reagent 
Experiment 1 
None 
Mersalyl 
p-Chloromercuribenzenesulphonate 
Mercuric chloride 
7V-Ethylmaleimide 
Pyridoxal 5'-phosphate 
Bathophenanthroline 
a-Cyanocinnamate 
Carboxyatractyloside 
Phenylsuccinate 
Butylmalonate 
Benzylmalonate 
1,2,3-Benzenetricarboxylate 
Experiment 2 
None 
Succinate 
Fumarate 
Methylfumarate 
Oxoglutarate 
Oxaloacetate 
L-Malate 
Maléate 
Malonate 
Citrate 
c/i-Aconitate 
Threo-Ds-isocitrate 
Phosphoenolpyruvate 
Phosphate 
Sulphate 
Glutamate 
Ornithine 
Pyruvate 
Carnitine 
Inhibition (%) 
-
94 
96 
75 
9 
94 
97 
6 
7 
79 
40 
80 
82 
-
87 
99 
95 
90 
81 
54 
30 
23 
33 
63 
95 
57 
8 
9 
- 2 
2 
10 
- 1 
Proteoliposomes were loaded with 20 mM fumarate and transport 
was started by adding 1.5 mM [14C]oxoglutarate. The incubation 
time was 1 min. Thiol reagents were added 2 min before the labelled 
substrate; the other inhibitors and external substrates were added 
together with [14C]oxoglutarate. All inhibitors and substrates were 
used at a concentration of 15 mM, except for mercurials and a-cya-
nocinnamate (0.1 mM), ./V-ethylmaleimide (2 mM), carboxyatractylo-
side (20 LiM), pyridoxal 5'-phosphate and bathophenanthroline (1 
mM). In experiments 1 and 2, respectively, the control values of un-
inhibited oxoglutarate/fumarate exchange were 1336 and 1207 nmol/ 
min per mg protein. Similar results were obtained in three independ-
ent experiments. 
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Fig. 3. Km values of reconstituted ACR1 for external oxoglutarate, succinate and fumarate. Lineweaver-Burk plots were obtained from back-
ward exchange measurements of initial [14C]oxoglutarate efflux rates. Non-radioactive oxoglutarate (A), fumarate (B) or succinate (C) was 
added at the concentrations indicated to proteoliposomes containing 20 mM [14C]oxoglutarate. See Section 2 for explanation of v'. 
constants, Km, for transport of non-radioactive succinate and 
fumarate can be determined by applying the backward ex-
change method [18]. Therefore, the internal substrate pool 
of proteoliposomes containing 20 mM oxoglutarate was la-
belled radioactively by carrier-mediated equilibration with ex-
ternal [14C]oxoglutarate. During this step, the internal sub-
strate concentration remained unchanged (oxoglutarate/ 
oxoglutarate homo-exchange). After removal of residual ex-
ternal radioactivity, export of [14C]oxoglutarate was initiated 
by addition of different concentrations of non-radioactive suc-
cinate or fumarate (in the absence of externally added sub-
strate, no efflux of radioactive oxoglutarate was observed, 
even after 60 min incubation). 
In order to verify that the backward exchange technique is 
applicable also to reconstituted ACR1, the Km value for ex-
ternal oxoglutarate was measured by the backward exchange 
procedure in the presence of 20 mM internal [14C]oxoglutarate 
and external oxoglutarate ranging from 0.66 to 5 mM (see 
Fig. 3A). The mean values obtained from this and three sim-
ilar experiments (1.86 ± 0.25 mM) agreed well with those from 
the forward exchange determinations (average values 
2.0 ±0.11 mM from 24 experiments). It should be noted 
that the different intercepts on the ordinates of Figs. 2 and 
3A, respectively, do not represent different Vmsx values for 
forward and backward exchange measurements, as the back-
ward exchange activities are given as apparent velocities (see 
Section 2). 
Having established the validity of the backward exchange 
method, the external Km values for fumarate and succinate 
were determined by this procedure. A linear reciprocal plot 
was obtained over ranges of 0.08-2.5 mM and 0.24-2.5 mM 
for external fumarate and succinate, respectively, with a con-
stant internal oxoglutarate concentration of 20 mM (Fig. 
3B,C). From a series of experiments of this type, a transport 
affinity (Km) of 0.36 ±0.08 mM for fumarate and 0.69 ±0.12 
mM for succinate were calculated (see Table 3). These Km 
values are similar to the inhibition constants (Ki) of succinate 
and fumarate, determined by measuring the reconstituted 
[14C]oxoglutarate/fumarate exchange in the presence of differ-
ent oxoglutarate concentrations and with a constant concen-
tration of either succinate or fumarate (Fig. 2). The mean 
values and standard errors of transport affinities and inhibi-
tion constants for several substrates of the reconstituted 
ACR1 protein are summarised in Table 3. Fumarate and suc-
cinate are the best substrates for reconstituted ACR1. Both 
the transport affinities and inhibition constants of fumarate 
are 2-fold lower than those of succinate, but they are about 6-
fold lower than those of oxoglutarate and oxaloacetate, and 
15-fold lower than those of malate. The transport affinities of 
citrate, isocitrate and phosphoenolpyruvate (which are the 
physiological substrates of the tricarboxylate carrier from 
both rat liver and S. cerevisiae [26,14], are very high ( > 6 
mM) and therefore they are not important physiologically. 
The dicarboxylates and tricarboxylates listed in Table 3, as 
well as phosphoenolpyruvate, are all competitive inhibitors, 
since they were found to increase the apparent Km without 
Table 3 
Kinetic parameters of reconstituted ACR1 
Substrate Km (mM) K¡ (mM) 
Fumarate 
Succinate 
Oxoglutarate (backward exchange) 
Oxoglutarate (forward exchange) 
Oxaloacetate 
L-Malate 
Citrate 
Threo-Ds-isocitrate 
Phosphoenolpyruvate 
0.36 ±0.08 (6) 
0.69 ±0.12 (6) 
1.86 ±0.25 (4) 
2.00 ±0.11 (24) 
1.93 ±0.28 (3) 
5.26 ±0.95 (3) 
n.d. 
6.17 ±0.97 (3) 
> 9.0 (2) 
0.32 ±0.06 (5) 
0.72 ±0.07 (6) 
n.d. 
n.d. 
2.15 ±0.23 (4) 
5.32 ±0.51 (3) 
9.86 ±0.88 (4) 
0.37 ±0.04 (4) 
4.40 ±0.53 (3) 
The Km values were determined by the backward exchange method using the experimental conditions described in Fig. 3B,C for fumarate and 
succinate. The Ki values were calculated from double reciprocal plots of the rate of [14C]oxoglutarate/fumarate exchange versus substrate concen-
tration, performed under the experimental conditions described in Fig. 2. The competing anions were added together with [14C]oxoglutarate at the 
appropriate concentrations. The values are averages± S.E.M. (n); n.d., not determined. 
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changing the Vmax of the [14C]oxoglutarate/fumarate exchange 
(data not shown). The inhibition constants of these com-
pounds are virtually coincident with their transport affinities, 
except for isocitrate and phosphoenolpyruvate where the Ki 
values are significantly lower than the respective Km values. 
The inhibition constant of isocitrate (0.37 mM) is particularly 
low, demonstrating that although it is poorly transported by 
ACRl, nonetheless it has a high affinity for the protein. In 
this context, it is worth noting that ACRl and the yeast cit-
rate carrier are 30% identical in sequence and ACRl is closer 
to the citrate carrier than any other member of the family. 
3.4. Conclusions 
The experiments described in this paper strongly suggest 
that ACRl is a transport protein in the inner membranes of 
yeast mitochondria that connects the anaplerotic production 
of succinate by the glyoxylate cycle in the cytosol with the 
tricarboxylic acid cycle and electron transfer by complex II 
(succinate dehydrogenase:ubiquinone reductase) in the mito-
chondrion. The cytoplasmic fumarate can be converted first to 
malate, and then to oxaloacetate, which is indispensable for 
gluconeogenesis and for the oxidation of acetyl-CoA that has 
not been consumed by the glyoxalate cycle. Therefore, a mu-
tation in ACRl would prevent the anaplerotic replenishment 
of oxaloacetate and block the tricarboxylic acid cycle. The 
consequent accumulation of acetyl-CoA could explain the 
low levels of acetyl-CoA synthase activity found in the 
ACRl defective strain [4]. The regulatory function of the suc-
cinate-fumarate transporter on acetyl-CoA synthase and the 
proposed mitochondrial location of ACRl will need to be 
verified by further experimentation. Neither the sequence of 
ACRl nor that of isocitrate lyase has any of the characteristic 
features that are associated with targetting to the glyoxysome 
[!]■ 
The procedure employed in this work for the bacterial over-
production of ACRl as inclusion bodies, and its functional 
reconstitution was first described for the bovine oxoglutarate/ 
malate carrier [17]. With minor modifications, it has proved to 
be a way of also producing active phosphate [12], citrate [14], 
dicarboxylate [5,13] and ornithine [15] carriers, and, as in the 
present instance, it has allowed the hitherto unknown yeast 
genes for the dicarboxylate and ornithine carriers to be iden-
tified. The prospects for identifying the biochemical functions 
of further members of the family of mitochondrial carrier 
proteins by similar means are excellent, and more distantly, 
the procedure could provide sufficient amounts of active 
transport proteins for crystallisation, thereby overcoming 
one of the major obstacles in their structural analysis [27]. 
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